imatinib pulmonary hypertension

Imatinib, a medication used for treating certain types of cancer, has been associated with pulmonary arterial hypertension (PAH), a severe lung condition characterized by abnormally high pressure in the pulmonary arteries. PAH can lead to symptoms such as shortness of breath, fatigue, and chest pain, potentially impacting heart function adversely.

It's important to note that not all patients on imatinib will develop PAH. Among those who do, the severity can vary significantly, with some experiencing mild symptoms and others facing more severe complications. The occurrence of PAH may be influenced by factors such as the dosage of imatinib, the duration of treatment, and other underlying health conditions.

For patients receiving imatinib, regular monitoring of pulmonary function and blood pressure is crucial. Should any symptoms of PAH emerge, such as difficulty breathing or chest pain, immediate medical attention is advised. Additionally, patients should adhere to their physician's recommendations for adjusting medication dosages and undergo treatment under medical supervision.